Tags

Type your tag names separated by a space and hit enter

In Vitro Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread.
Antimicrob Agents Chemother. 2017 03; 61(3)AA

Abstract

Treatments for Clostridium difficile infection remain limited, despite the introduction of fidaxomicin, and development of new agents is necessary. We determined the in vitro susceptibilities of 199 prevalent or emerging Clostridium difficile PCR ribotypes to MCB3681, a novel investigational quinolonyl-oxazolidinone, and 8 comparators (metronidazole, vancomycin, fidaxomicin, moxifloxacin, ciprofloxacin, clindamycin, tigecycline, and linezolid). MCB3681 showed good activity against C. difficile with no evidence of MCB3681 resistance in isolates showing either moxifloxacin or linezolid resistance or both moxifloxacin and linezolid resistance.

Links

Publisher Full Text
ncbi.nlm.nih.gov
aac.asm.org
PMC Free PDF

Authors+Show Affiliations

Freeman J
Microbiology, Leeds Teaching Hospitals Trust, University of Leeds, Leeds, United Kingdom Jane.freeman4@nhs.net. Healthcare Associated Infections Research Group, Leeds Institute for Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom.
Pilling S
Healthcare Associated Infections Research Group, Leeds Institute for Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom.
Vernon J
Healthcare Associated Infections Research Group, Leeds Institute for Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom.
Wilcox MH
Microbiology, Leeds Teaching Hospitals Trust, University of Leeds, Leeds, United Kingdom. Healthcare Associated Infections Research Group, Leeds Institute for Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom.

MeSH

AminoglycosidesAnti-Bacterial AgentsClostridium difficileDrug Resistance, Multiple, BacterialEnterocolitis, PseudomembranousFluoroquinolonesHumansLinezolidMicrobial Sensitivity TestsMoxifloxacinOxazolidinonesPolymerase Chain ReactionPyrrolidinesQuinolonesRibotyping

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

27993853

Citation

Freeman, Jane, et al. "In Vitro Activities of MCB3681 and Eight Comparators Against Clostridium Difficile Isolates With Known Ribotypes and Diverse Geographical Spread." Antimicrobial Agents and Chemotherapy, vol. 61, no. 3, 2017.
Freeman J, Pilling S, Vernon J, et al. In Vitro Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread. Antimicrob Agents Chemother. 2017;61(3).
Freeman, J., Pilling, S., Vernon, J., & Wilcox, M. H. (2017). In Vitro Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread. Antimicrobial Agents and Chemotherapy, 61(3). https://doi.org/10.1128/AAC.02077-16
Freeman J, et al. In Vitro Activities of MCB3681 and Eight Comparators Against Clostridium Difficile Isolates With Known Ribotypes and Diverse Geographical Spread. Antimicrob Agents Chemother. 2017;61(3) PubMed PMID: 27993853.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In Vitro Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread. AU - Freeman,Jane, AU - Pilling,Sally, AU - Vernon,Jonathan, AU - Wilcox,Mark H, Y1 - 2017/02/23/ PY - 2016/09/27/received PY - 2016/12/03/accepted PY - 2016/12/21/pubmed PY - 2017/9/28/medline PY - 2016/12/21/entrez KW - Clostridium difficile KW - MCB3681 KW - antimicrobial susceptibility JF - Antimicrobial agents and chemotherapy JO - Antimicrob. Agents Chemother. VL - 61 IS - 3 N2 - Treatments for Clostridium difficile infection remain limited, despite the introduction of fidaxomicin, and development of new agents is necessary. We determined the in vitro susceptibilities of 199 prevalent or emerging Clostridium difficile PCR ribotypes to MCB3681, a novel investigational quinolonyl-oxazolidinone, and 8 comparators (metronidazole, vancomycin, fidaxomicin, moxifloxacin, ciprofloxacin, clindamycin, tigecycline, and linezolid). MCB3681 showed good activity against C. difficile with no evidence of MCB3681 resistance in isolates showing either moxifloxacin or linezolid resistance or both moxifloxacin and linezolid resistance. SN - 1098-6596 UR - https://www.unboundmedicine.com/medline/citation/27993853/In_Vitro_Activities_of_MCB3681_and_Eight_Comparators_against_Clostridium_difficile_Isolates_with_Known_Ribotypes_and_Diverse_Geographical_Spread_ L2 - http://aac.asm.org/cgi/pmidlookup?view=long&pmid=27993853 DB - PRIME DP - Unbound Medicine ER -